beta
Trial Radar AI
Clinical Trial NCT06838273 for Non-small Cell Lung Cancer is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3 720 Randomized Open-Label

Recruiting
Clinical Trial NCT06838273 is designed to study Treatment for Non-small Cell Lung Cancer. It is a Phase 3 interventional study that is recruiting, having started on February 24, 2025, with plans to enroll 720 participants. Led by Sichuan Baili Pharmaceutical Co., Ltd., it is expected to complete by December 1, 2028. The latest data from ClinicalTrials.gov was last updated on September 24, 2025.
Brief Summary
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.
Official Title

A Phase III Randomized Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Conditions
Non-small Cell Lung Cancer
Other Study IDs
  • BL-B01D1-308
NCT ID Number
NCT06838273
Start Date (Actual)
2025-02-24
Last Update Posted
2025-09-24
Completion Date (Estimated)
2028-12
Enrollment (Estimated)
720
Study Type
Interventional
PHASE
Phase 3
Status
Recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalBL-B01D1 in Combination with Osimertinib
Participants receive BL-B01D1 in Combination with Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
BL-B01D1
Administration by intravenous infusion for a cycle of 3 weeks.
Osimertinib
Oral administration, 80mg daily for a cycle of 3 weeks.
Active ComparatorOsimertinib
Participants receive Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Osimertinib
Oral administration, 80mg daily for a cycle of 3 weeks.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Progression-free survival (PFS)
Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.
Up to approximately 36 months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Overall survival (OS)
Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.
Up to approximately 36 months
Objective Response Rate (ORR)
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).
Up to approximately 36 months
Disease Control Rate (DCR)
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.
Up to approximately 36 months
Duration of Response (DOR)
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.
Up to approximately 36 months
Treatment Emergent Adverse Event (TEAE)
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.
Up to approximately 36 months
Anti-drug antibody (ADA)
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated.
Up to approximately 36 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. Sign the informed consent form voluntarily and follow the protocol requirements;
  2. Age ≥18 years old;
  3. Expected survival time ≥3 months;
  4. Patients with unresectable or radical radiotherapy for locally advanced non-small cell lung cancer;
  5. Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;
  6. Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;
  7. At least one measurable lesion meeting the RECIST v1.1 definition was required;
  8. ECOG 0 or 1;
  9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
  10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
  11. The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period;
  12. Urinary protein ≤2+ or < 1000mg/24h;
  13. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

  1. Previous histologic or cytological evidence of small cell or mixed small/non-small cell components;
  2. Patients with previous systemic therapy;
  3. Patients had received EGFR-TKI therapy;
  4. Studies received radical radiotherapy, major surgery, and large area radiotherapy within 4 weeks before randomization;
  5. History of severe heart disease and cerebrovascular disease;
  6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;
  7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
  8. Were diagnosed with active malignancy within 3 years before randomization;
  9. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure &gt; 150 mmHg or diastolic blood pressure &gt; 100 mmHg);
  10. Patients with poor glycemic control;
  11. A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis, or a suspicion of such disease;
  12. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
  13. Patients with active central nervous system metastasis;
  14. Had a severe infection within 4 weeks before randomization;
  15. Patients with massive or symptomatic effusions or poorly controlled effusions;
  16. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;
  17. Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
  18. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
  19. Patients with a history of inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;
  20. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;
  21. Had autologous or allogeneic stem cell transplantation history;
  22. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;
  23. A history of severe neurological or psychiatric illness;
  24. Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;
  25. Subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;
  26. Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.
Sichuan Baili Pharmaceutical Co., Ltd. logoSichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. logoBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Study Central Contact
Contact: Sa Xiao, PHD, 15013238943, [email protected]
1 Study Locations in 1 Countries

Shanghai Municipality

Shanghai East Hospital, Shanghai, Shanghai Municipality, China
Caicun Zhou, Contact
Recruiting